All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Bookmark this article
During the EHA 2022 Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson Cancer Center, Houston, US. We asked, Could the use of granulocyte colony-stimulating factor (G-CSF) post-remission improve outcome?
Could the use of G-CSF post-remission improve outcome?
DiNardo outlines the recently presented post-hoc analysis, which found shorter incidence of neutropenia in patients who received G-CSF. Finally, DiNardo discusses the impact of G-CSF on the overall survival, highlighting an improved remission in venetoclax-treated patients.
What is the real-world experience of R/R AML treatment with venetoclax + HMAs?
During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory...
1st NCRI AML academy meeting | What is the optimum treatment strategy for elderly or frail patients with AML?
Prof Courtney DiNardo spoke to us at the 1st NCRI AML academy meeting on the topic of the optimum strategy for the treatment of elderly or...
Subscribe to get the best content related to AML delivered to your inbox